Initial treatment of community-acquired pneumonia (CAP) is usually empirical because the microbial etiology cannot be predicted on the basis of clinical presentation and because accurate and reliable rapid diagnostic methods to identify specific pathogens are not currently available for most cases. Guidelines published by the Infectious Diseases Society of America and the American Thoracic Society provide consensus recommendations for initial antimicrobial treatment of CAP [1] .
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Although many antimicrobial agents are approved for the treatment of CAP, guidelines for empirical treatment for hospitalized patients provide specific recommendations for antibiotic selection. For instance, recommendations for patients who are not admitted to the intensive care unit (ICU) include the combination of a b-lactam plus a macrolide or monotherapy with a fluoroquinolone [1] . These recommendations are primarily based on the findings from observational studies that have demonstrated a reduction in mortality among patients given treatment with a b-lactam plus a macrolide or monotherapy with a fluoroquinolone, compared with patients given treatment with a cephalosporin alone [2] [3] [4] [5] . In addition, a number of observational studies have suggested improved patient outcomes for patients who receive guideline-concordant antimicrobial therapy [6] [7] [8] [9] [10] [11] .
In 1994, the Centers for Medicare & Medicaid Services began data collection from a large national cohort of inpatients with pneumonia, data that Gleason et al. [2] evaluated for the relationship between initial anti- Using these data, we have studied the relationship between the initial antibiotic regimen and patient mortality and present the results here. In addition, we discuss some of the limitations of using nonexperimental cohort studies to evaluate associations between care processes and patient outcomes.
METHODS
The National Pneumonia Project Study population. We applied multiple exclusion criteria (table 1) to produce an analytic database representing patients who had a radiographically supported working diagnosis of pneumonia at the time of admission, were admitted for curative therapy, were aged у65 years, and were immunocompetent. We limited analysis to CAP by excluding patients who had been in the hospital during the 14 days before admission and by excluding patients who resided in a long-term-care facility. Only the first of a patient's multiple hospitalizations was included in the analysis. Cases with death or discharge on the day of admission were excluded. Geographic regions were those used for the US Census (i.e., West, Midwest, South, and Northeast). We calculated the pneumonia severity index (PSI) score for each patient [14] .
Patients from the 2 cohorts were then classified into groups by initial antimicrobial regimen. Only antimicrobials administered within the first 36 h after hospital arrival were considered in the classification of patients. All antimicrobials administered within the first 36 h were first grouped into 7 mutually exclusive categories, including macrolides, fluoroquinolones, b-lactam/ b-lactamase inhibitors, aminoglycosides, second-and thirdgeneration cephalosporins, and other. Fluoroquinolones and macrolides were evaluated if they were administered orally or parenterally. All other antimicrobials had to be administered parenterally to be included in subsequent analyses with orally administered antibiotics assigned to the "other" regimen. Patients were then assigned to 1 of 9 initial antimicrobial regimens, composed of the 6 of the 7 previously mentioned categories (excluding second-generation cephalosporin monotherapy) and 3 combinations: macrolide plus cephalosporin (second or third generation), fluoroquinolone plus cephalosporin (second or third generation), and macrolide plus blactam/b-lactamase inhibitor. Any other antimicrobials or combination of antimicrobials not classified into one of these groups was put into the "other" regimen group. The definitions for the monotherapy and dual-therapy regimens were strict, meaning that the patient could not receive any additional antimicrobials within 36 h after hospital arrival.
Data analysis. At univariate analysis, differences across selected subgroups were assessed using x 2 tests and ORs for categorical variables. Multivariate logistic regression was used to produce adjusted ORs (AORs) that describe the association between antibiotic selection and clinical outcomes while controlling for potential confounding. We analyzed the 2 cohorts of patients separately and as a combined population. Because the results were similar for the 2 cohorts, we present the analyses of the combined cohort in this article. The multivariate model adjusted for age, sex, neoplastic disease, cardiovascular disease, altered mental status, respiratory rate у30 breaths/min, systolic blood pressure !90 mm Hg, temperature !35ЊC or у40ЊC, pulse у125 beats/min, arterial pH !7.35, blood urea nitrogen level 111 mmol/L, sodium level !130 mEq/L, hematocrit !30%, partial pressure of oxygen !60 mm Hg, and presence of pleural effusion. In addition, admission to the intensive care unit and first antibiotic dose within 4 h after hospital arrival were included in the multivariate model. The association between antibiotic selection and patient mortality was also assessed by calculating mortality rate, stratified on the basis of the initial PSI score.
To evaluate the impact of clustering of care within hospitals on patient outcomes, we first examined the number cases included in each hospital and examined the mean, median, and range of number of cases per facility. We used the generalized linear mixed model (SAS PROC GLIMMIX) for outcomes, including hospital as a random cluster effect. We compared the model results from GLIMMIX to those from multiple logistic regression models. Because of the limited number of cases sampled at the individual hospital level, the results of this analysis were similar to those found in multivariate analysis and are not presented here.
All analyses were completed using SAS statistical software (version 9.1.3; SAS Institute). P values are 2 sided. Statistical significance is defined by a 95% CI that excludes 1.0 or by . P ! .05 (table 1) . The number of cases analyzed by hospital ranged from 1 to 122 cases in each of the 2 cohorts (median, 3 cases per hospital for both cohorts). Patient demographic characteristics are summarized in table 2. Although there were some statistically significant differences between 1998-1999 and 2000-2001 in the patient population, the absolute differences were small. In-hospital, 14-day, and 30-day mortality rates all decreased from 1998-1999 to 2000-2001; however, readmission rates were increased. Patient clinical characteristics are summarized in table 3. There were significant but relatively small absolute differences in the proportion of patients admitted with congestive heart failure, cerebrovascular disease, chronic renal disease, altered mental status, tachypnea, hypotension, and elevation of blood urea nitrogen level. The proportion of patients admitted to the ICU decreased in 2000-2001, as did the proportion of patients in PSI risk classification V.
RESULTS

From
Unadjusted patient mortality for non-ICU and ICU patients stratified by initial antimicrobial regimen is summarized in ta- ble 4. The in-hospital and 30-day mortality rates for patients not admitted to the ICU within 24 h after arrival were 3.6% and 7.1%, respectively. For those patients admitted to the ICU, the in-hospital and 30-day mortality rates were 14.1% and 18.0%, respectively.
AORs for in-hospital, 14-day, and 30-day mortality, stratified by ICU admission and by initial antimicrobial treatment, are summarized in table 5. For non-ICU patients, initial treatment with fluoroquinolone monotherapy was associated with reduced in-hospital, 14-day, and 30-day mortality rates (AOR for 30-day mortality, 0.7; 95% CI, 0.6-0.9;
). The com-P p .001 bination of a cephalosporin plus a macrolide was associated with a reduced 14-day and 30-day mortality (AOR for 30-day mortality, 0.7; 95% CI, 0.6-0.9;
). For ICU patients, the P ! .001 use of an aminoglycoside was associated with the elevated risk of death during the hospital stay, at 14 days, and at 30 days after admission (AOR at 30 days, 2.2; 95% CI, 1.4-3.5; P p ). The combination of a cephalosporin plus a macrolide .001 was associated with a reduced risk of in-hospital mortality (AOR, 0.6; 95% CI, 0.3-0.9;
) but not associated with P p .018 significant reductions in 14-day or 30-day mortality rate.
AORs for 30-day mortality, stratified by discharge time frame and by initial antimicrobial treatment, are summarized in table 6. Significant reductions in risk of death were noted for macrolide monotherapy (AOR, 0.3; 95% CI, 0.1-0.6; ), P p .001 fluoroquinolone monotherapy (AOR, 0.7; 95% CI, 0.6-0.9; ), and the combination of a cephalosporin plus mac-P p .003 rolide (AOR, 0.6; 95% CI, 0.5-0.8;
) for patients dis-P ! .001 charged in October-December. Patients given treatment with the combination of a cephalosporin plus a macrolide and discharged in January-March also had reduced mortality (AOR, 0.6; 95% CI, 0.4-0.9;
). We also evaluated the rela-P p .022 tionship between initial antimicrobial selection and patient outcomes stratified by region of the country (data not shown). At 30 days, significant reductions in mortality were demonstrated with the combination of a cephalosporin plus a macrolide in the Northeast (AOR, 0.6; 95% CI, 0.4-1.0; ), South P p .05 (AOR, 0.7; 95% CI, 0.5-0.9; ), and West (AOR, 0.7; P p .01 95% CI, 0.5-0.9;
). Fluoroquinolone monotherapy was P p .01 associated with significant reductions in mortality in the South (AOR, 0.7; 95% CI, 0.5-0.9;
) and West (AOR, 0.7; 95% P ! .01 CI, 0.5-1.0;
). With the exception of increased mortality P p .03 among those patients receiving an aminoglycoside, no other statistically significant associations were noted between anti- The marked increase in the number of patients receiving the "other" regimen is primarily because of patients to whom у3 antibiotics were administered within 36 h after hospital arrival.
biotic selection and 30-day mortality rate for patients discharged from a hospital in the Midwest region during the time frames studied. AORs for 30-day mortality, stratified by PSI score and by initial antimicrobial treatment, are summarized in table 7. Treatment with macrolide monotherapy (AOR, 0.5; 95% CI, 0.3-0.8; ), fluoroquinolone monotherapy (AOR, 0.7; P p .003 95% CI, 0.6-0.9;
), and the combination of a ceph-P p .001 alosporin plus a macrolide (AOR, 0.7; 95% CI, 0.6-0.8; P ! ) resulted in lower odds of mortality for patients in PSI .001 risk classes IV and V. No significant associations between antibiotic selection and 30-day mortality were noted for patients in PSI risk classes II and III.
National trends in initial antibiotic treatment for Medicare patients admitted to the hospital with pneumonia, stratified by care in the ICU or in a non-ICU ward, are summarized in table 8. Consistent with guideline recommendations and national performance measures that are publicly reported for hospitals, use of second-and third-generation cephalosporin monotherapy has decreased dramatically, whereas the use of fluoroquinolone monotherapy and combination therapy with a cephalosporin plus a macrolide have increased. Patients receiving у3 antimicrobials within 36 h after hospitalization have increased substantially-particularly among the population of ICU patients.
DISCUSSION
Our findings are similar to those of other observational studies demonstrating an association between antibiotic selection and patient outcomes [2] [3] [4] [5] [15] [16] [17] [18] . The magnitude of benefit of fluoroquinolone monotherapy or a cephalosporin plus a macrolide, compared with third-generation cephalosporin monotherapy, was similar to that demonstrated by Gleason et al. [2] . We found greater benefit of fluoroquinolone monotherapy and of a cephalosporin plus a macrolide for patients with moresevere pneumonia (PSI risk classes IV and V). However, for the 10.6% of our sample who were admitted to the ICU, we found no association between antibiotic selection and patient mortality.
Although our results are consistent with those of a number of other studies highlighting the association between antimicrobial selection and patient outcomes, the benefit of giving patients treatment with respiratory fluoroquinolones or the combination of a cephalosporin plus a macrolide has been challenged [19] [20] [21] [22] [23] [24] . Multiple issues have been raised about using a nonexperimental cohort study to identify associations between a process of care (such as antibiotic selection) and patient outcomes. Perhaps the greatest risk is the potential for residual confounding of patient outcomes due to unmeasured variables [19, 23, 24] . The finding in our study and similar findings by Gleason et al. [2] that macrolide monotherapy was associated with a reduced 30-day risk-adjusted mortality and that the use of any aminoglycoside was associated with elevated risk-adjusted 30-day mortality in patients with pneumonia in PSI risk classes IV and V highlight this concern. As noted by others, the use of macrolide monotherapy for patients with pneumonia may actually be a marker of less-severe disease, as determined by the clinician at the bedside. Similarly, the use of an aminoglycoside may reflect a clinical decision at the bedside to use the agent in a patient with severe pneumonia. It is possible that unmeasured clinical variables prevent adequate risk adjustment of patient outcomes and result in the findings demonstrated in our study and the studies of others. Another controversy raised about the evaluation of antibiotic selection and patient outcomes is the time frame after admission that should be used to assess outcomes such as mortality [25] . Are deaths at 30 days after a pneumonia hospitalization attributable to decisions made about antibiotic selection at the time of hospital admission? Finally, our study and others have been limited to patients in the Medicare-eligible age group because of the ability to follow up with patients for outcomes such as readmission and death on the basis of administrative data. The results of this study may not be generalizable to other populations.
Despite the limitations, observational studies do present some advantages for evaluating the association between processes of care and outcomes. The most obvious advantage is the very large sample of patients available for evaluation in studies from efforts such as the National Pneumonia Project. In addition to being relatively cost-effective, observational studies allow investigators to test hypotheses that might not be considered ethical in a prospective study (e.g., evaluating the association between delayed antibiotic delivery and patient outcomes). Because the treatment effect of choosing one antibiotic combination over another may result in relatively small absolute differences in mortality, the number of patients who would be required in a prospective study sample to evaluate the outcome of interest may be prohibitive. We estimate, for example, that, on the basis of a 30-day mortality rate of 8.4%
for a community-dwelling Medicare patient who was admitted to a non-ICU hospital bed, it would take 12700 patients per treatment arm to demonstrate a 2% absolute reduction in mortality of an investigational antibiotic, compared with third-generation cephalosporin monotherapy. In addition, observational studies may allow for evaluation of a population of patients from the community setting that is more representative than the population often enrolled in prospective, randomized trials on the basis of strict study enrollment criteria [26] .
How might the results of our study and other observational studies help to inform the design of clinical trials of antibiotic therapy for pneumonia? Observational studies provide useful information about the likely clinical response to treatment and the likelihood of outcomes, such as death and readmission, for large populations of patients with pneumonia. This will clearly inform sample-size considerations for prospective clinical trials. The results of observational studies may also inform the magnitude of the absolute differences in outcomes between various treatment regimens, which would also inform the design of clinical trials, including sample-size considerations. Finally, observational studies may identify unforeseen issues that could have an impact on the evaluation of a clinical trial. For instance, the results of our study suggest that outcomes of pneumonia, stratified by antibiotic selection, may vary with both the region of the country in which the patient is hospitalized and the time of the year of hospitalization (perhaps linked to coexistent viral infections or differences in the prevalence in infections caused by atypical organisms).
CONCLUSION
In summary, our study of community-dwelling patients with pneumonia who were admitted to the hospital demonstrated that initial antimicrobial treatment with the combination of a second-or third-generation cephalosporin plus a macrolide or initial treatment with a fluoroquinolone was associated with a reduced 30-day mortality rate, compared with treatment with third-generation cephalosporin monotherapy in the non-ICU population. Although our results are consistent with those of other observational studies of antibiotic selection and patient outcomes in pneumonia, controversy continues to exist about the use of nonexperimental cohort studies to demonstrate associations between processes of care, such as antibiotic selection, and patient outcomes. This study continues to identify the need for randomized trials to definitively answer questions about antibiotic selection and patient mortality. The results of these large-scale observational studies may provide useful information that will inform decisions in the development and design of future randomized trials of antimicrobial treatment for patients with pneumonia.
